Photo: UWE_UMSTAETTER/Getty Images
Brazil-based Axenya, a company specializing in corporate healthcare and care for individuals with chronic health conditions, has secured $12 million (BRL 65 million) in Series A funding.
Canary co-led the round along with Indicator Capital and Zentynel.
WHAT IT DOES
The company provides patients with chronic diseases such as diabetes, high blood pressure and chronic obstructive pulmonary disease with easy access to tools to help them cope and take control of their condition.
Axenya connects and integrates specialized tools to form digital therapeutics, which support patients to take the proper medication at the right time and monitor their heart rate and blood sugar levels.
Axenya is also building digital therapeutics programs that will give providers insight into patient behavior and receive pre-digested and actionable information about a patient's condition.
The company will use the funds to promote commercial development and its technology platform.
Mariano Garcia-Valiño, founder and CEO of Axenya, said the company sets itself apart by the combination of cutting-edge technology and a business model that is able to structurally transform the system.
"In healthcare, having a great product is not enough, you need a business model that can reshape the system," Garcia-Valiño said in a statement.
MARKET SNAPSHOT
Other companies in the chronic care management space include Hinge Health, which earlier this month announced a 55% increase in total second-quarter revenue for 2025 of $139.1 million from $89.8 million in Q2 2024. The company went public on the NYSE in May.
In April, Hinge Health partnered with Cigna Healthcare to provide its self-insured clients with access to Hinge's digital musculoskeletal care platform.
Cigna's members who chose to enroll had access to Hinge Health through Cigna's condition-specific care program, Pathwell Bone and Joint Solution.
Another company in the space is Omada, which began trading on the Nasdaq under the ticker symbol OMDA on June 6 at a public offering price of $19 per share.
The company raised $150 million in its IPO. The company's stock is trading at around $23 per share.
Current Health offers a healthcare-at-home technology platform that utilizes biosensors to monitor a patient’s condition and recognize when they may need help from a clinician.
In June, Christopher McGhee, the cofounder and former CEO of Current Health, announced he reacquired the company from Best Buy and will return as the company's CEO.
Best Buy acquired Current Health in 2021 for $400 million, building on the retail giant's previous investments in senior care and remote patient monitoring.
